Thallous Chloride Tl 201 Injection, Solution
FDA Label NDC 69945-120

26 label sections · Submitted to the FDA by Curium Us Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Curium Us Llc for the product Thallous Chloride Tl 201 (NDC 69945-120). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 radiation safety – drug handling, 2.2 recommended dose, 2.3 administration and imaging instructions, 2.4 radiation dosimetry, 3 dosage forms and strengths, 4 contraindications, 5.1 hypersensitivity reactions, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

8.5 Geriatric Use

Clinical studies of Thallous Chloride Tl 201 Injection for myocardial perfusion imaging did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently from younger subjects. Other reported experience has not revealed clinically relevant differences in the response of elderly in comparison to younger patients.


This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

12.2 Pharmacodynamics

The pharmacodynamics of thallous chloride Tl 201 have not been established.

17 Patient Counseling Information

Radiation Risk
Advise patients of the radiation risk of Thallous Chloride Tl 201 Injection. Instruct patients to drink water to ensure adequate hydration prior to administration of Thallous Chloride Tl 201 Injection and to continue drinking and voiding frequently following administration to reduce radiation exposure [see Warnings and Precautions ( 5.3)] .


Pregnancy
Inform pregnant women of the risk of fetal exposure to radiation dose if they undergo an imaging procedure with Thallous Chloride Tl 201 Injection [see Use in Specific Populations ( 8.1)] .


Lactation
Advise a lactating woman to temporarily discontinue breastfeeding and to pump and discard breastmilk for at least 96 hours after administration of Thallous Chloride Tl 201 Injection to minimize radiation exposure to a breastfed infant [see Use in Specific Populations ( 8.2)] .

Manufactured by:

Curium US LLC
Maryland Heights, MO 63043

Made in USA

©2025 Curium US LLC. Curium TMand the Curium logo are trademarks of a Curium company.

A120I0

CURIUM™

* Please review the disclaimer below.